Baxter International Inc vs InMode Ltd — how do they compare? Baxter International Inc trades at $26.9 (market cap $13.93B), while InMode Ltd trades at $15.19 (market cap $876.40M). The key difference: Baxter International Inc is far larger — about 15.9× InMode Ltd's market cap, and Baxter International Inc pays a 0.15% dividend while InMode Ltd pays none. Which is the better fit depends on your goals.
| BAX | INMD | |
|---|---|---|
Market Cap | $13.93B | $876.40M |
Sector | Health | Technology |
52-Week High | $28.35 | $16.62 |
52-Week Low | $15.80 | $12.76 |
Enterprise Value | $21.45B | $379.73M |
Dividend Yield | 0.15% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.05, down 2.03% today, with a bullish technical signal from moving averages but mixed oscillators. Recent Q2 2026 earnings beat expectations with EPS of $0.56 versus $0.37, and the company raised its 2026 guidance, reflecting operational improvements. However, fundamentals show challenges with a negative net income margin of -9.27% and elevated P/E of 87.85, though revenue trends are stabilizing near $11.5 billion for 2026.
The outlook is cautiously optimistic due to earnings beats and raised guidance, but high valuation and persistent losses pose risks. Analyst consensus is mixed with 42% buy ratings and a $25.43 price target below the current price, suggesting limited upside. Key risks include margin pressure and high debt levels, requiring sustained execution for stock appreciation.
INMD trades at $15.23, up 0.59% on the day, with a neutral technical signal and mixed earnings history including a Q1 2026 miss. Valuation ratios appear attractive with a P/E of 12.59 and EV/EBITDA of 5.43, while profitability remains strong with a net income margin of 20.69%. Recent news highlights an unsolicited acquisition offer from Steel Partners at $16.75 per share and ongoing shareholder disputes.
The stock presents a cautious opportunity given its undervaluation and robust cash flow, but risks include earnings volatility, governance tensions, and a securities fraud investigation. Analyst consensus is divided with 45% buy ratings, reflecting uncertainty around the acquisition outcome and future execution.
Trailing returns across standard periods
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →